Boehringer presents volasertib Phase II AML data

Boehringer Ingelheim GmbH (Ingelheim, Germany) presented interim data from the Phase II portion of a Phase I/II trial of volasertib to treat newly diagnosed acute myelogenous leukemia (AML). Intravenous injections of volasertib plus low-dose cytarabine (LDAC) non-significantly improved the primary endpoint of objective response rate (ORR) vs. LDAC alone (31% vs. 13.3%, p=0.0523). Volasertib plus LDAC significantly improved the secondary endpoint of median event-free survival vs. LDAC alone (5.6 vs. 2.3 months, p=0.0237). ...